The use of CRISPR-Cas9 technology for genome editing has revolutionized the field of genetic engineering by allowing for

Core Concept

PILLAR 1 — MOLECULAR/CONCEPTUAL MECHANISM

Step-by-Step Analysis

CRISPR-Cas9 technology exploits an adaptive immune mechanism originally characterized in Streptococcus pyogenes and related prokaryotes. The system centers on two molecular components: a single-guide RNA (sgRNA) approximately 100 nucleotides long, and the Cas9 endonuclease, a ~160 kilodalton protein with two distinct nuclease domains—RuvC and HNH. The sgRNA contains a programmable ~20-nucleotide spacer region whose ribonucleotide sequence forms Watson-Crick base pairs (hydrogen bonds between complementary nitrogenous bases) with one strand of a target DNA locus. Adjacent to the target site, Cas9 must recognize a short sequence called the protospacer adjacent motif (PAM); for S. pyogenes Cas9, this is 5′-NGG-3′. PAM recognition triggers local DNA strand separation, allowing the spacer segment of the sgRNA to interrogate the exposed single-stranded DNA through thermodynamically driven base-pairing. When sufficient complementarity is achieved, conformational rearrangements within the Cas9 protein activate both nuclease domains: the HNH domain cleaves the DNA strand complementary to the sgRNA, while the RuvC domain cleaves the noncomplementary strand, generating a blunt-ended double-strand break (DSB) precisely three base pairs upstream of the PAM.

Why Other Options Are Wrong

The cell subsequently repairs this DSB through one of two pathways. Nonhomologous end joining (NHEJ) ligates the broken ends without a template, frequently introducing small insertions or deletions (indels) that disrupt the reading frame and produce a nonfunctional gene product—a knockout. Alternatively, homology-directed repair (HDR) uses an exogenously supplied donor DNA template bearing homologous flanking sequences, enabling precise nucleotide substitutions, insertions, or corrections at the targeted locus. It is this programmable specificity—driven entirely by the ribonucleotide sequence of the guide RNA—that distinguishes CRISPR-Cas9 from earlier genome modification tools such as zinc-finger nucleases or TALENs, which require labor-intensive protein engineering for each new target.

PILLAR 2 — STEP-BY-STEP LOGIC

The question stem asks what CRISPR-Cas9 allows, emphasizing its revolutionary impact on genetic engineering. Tracing the mechanism above, the key insight is that the sgRNA can be redesigned in silico and synthesized de novo to target virtually any gene sequence adjacent to a PAM. Researchers simply modify the 20-nucleotide spacer to match the locus of interest. When introduced into a cell alongside the Cas9 gene or protein, the complex homes to that single genomic location among billions of base pairs and introduces a targeted DSB. The subsequent repair outcome—disruptive indel or precise templated edit—is determined experimentally. This programmable, nucleotide-level accuracy at a user-selected locus constitutes precise editing of specific genes, making option C the correct answer. Older gene-transfer methods such as Agrobacterium-mediated transformation, electroporation, or viral transduction insert exogenous DNA into random genomic positions without sequence-level control, producing variable expression and potential insertional mutagenesis. CRISPR-Cas9 overcomes this limitation by directing edits to an exact chromosomal coordinate.

Furthermore, the same Cas9 protein can be repurposed: a catalytically dead variant (dCas9) in which the RuvC (D10A) and HNH (H840A) active sites are mutated can still be guided to specific loci to recruit transcriptional activator or repressor domains, enabling reversible gene regulation without altering the DNA sequence itself. This versatility further underscores that precision at defined genomic positions—not bulk transfer or nonspecific upregulation—is the hallmark innovation.

PILLAR 3 — DISTRACTOR ANALYSIS

Option A, increased efficiency of gene transfer, traps students who conflate genome editing with gene delivery methods such as bacterial transformation, viral transduction, or microinjection. CRISPR-Cas9 does not itself transfer exogenous genes into cells; rather, it edits nucleotides already present in the genome. The flaw is confusing the delivery vector (plasmid, ribonucleoprotein complex) with the editing activity. While transformation or electroporation may be used to introduce CRISPR components, this is mechanistically separable from what makes the technology revolutionary.

Option B, enhanced gene expression, appeals to students who recall that CRISPR-dCas9 fusion proteins can modulate transcription. However, the stem explicitly refers to genome editing, and the standard CRISPR-Cas9 system creates targeted DSBs—it does not inherently amplify transcription of any locus. Enhanced expression might be a downstream consequence of inserting a strong promoter near a gene, but this is an application, not the defining capability. The distractor exploits a superficial association between CRISPR and gene activation rather than the mechanistic basis of the tool.

Option D, reduced cost of production, reflects a real-world advantage—CRISPR reagents are less expensive than custom-engineered protein nucleases—but cost reduction is an economic outcome, not a molecular biological capability. The question asks what CRISPR allows for in the context of genome editing, demanding a mechanistic answer grounded in molecular function. Choosing D reflects a failure to distinguish between practical advantages and the core scientific mechanism that constitutes the breakthrough.